Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on July 20, 2009

Hypertension. 2009
Published online before print July 20, 2009, doi: 10.1161/HYPERTENSIONAHA.109.134932
A more recent version of this article appeared on September 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
54/3/583    most recent
HYPERTENSIONAHA.109.134932v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wilson, R. M.
Right arrow Articles by Sam, F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson, R. M.
Right arrow Articles by Sam, F.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Failure
*High Blood Pressure
Hazardous Substances DB
*HYDRALAZINE HYDROCHLORIDE
*ISOSORBIDE DINITRATE
Related Collections
Right arrow Structure
Right arrow Other heart failure
Right arrow Remodeling
Right arrow Animal models of human disease
Right arrow Hypertrophy

Submitted on April 20, 2009
Revised on May 12, 2009

Effects of Fixed-Dose Isosorbide Dinitrate/Hydralazine on Diastolic Function and Exercise Capacity in Hypertension-Induced Diastolic Heart Failure

Richard M. Wilson; Deepa S. De Silva; Kaori Sato; Yasuhiro Izumiya; and Flora Sam*

From the Whitaker Cardiovascular Institute (R.M.W., D.S.D.S., K.S., Y.I., F.S.), Cardiovascular Section (F.S.), and Evans Department of Medicine (F.S.), Boston University School of Medicine, Boston, Mass.

* To whom correspondence should be addressed. E-mail: flora.sam{at}bmc.org.

Abstract—Hypertension-induced diastolic heart failure accounts for a large proportion of all heart failure presentations. Hypertension also induces left ventricular (LV) hypertrophy. Fixed-dose isosorbide dinitrate/hydralazine (HISDN) decreased mortality in human systolic heart failure but it is unknown whether it improves maladaptive myocardial remodeling. We sought to test the hypothesis that chronic HISDN modulates LV hypertrophy and myocardial remodeling in hypertension-induced diastolic heart failure. FVB mice underwent either saline (n=18) or aldosterone (n=28) infusion. All underwent uninephrectomy and drank 1% salt water for 4 weeks. Mice were randomized after surgery to regular chow or chow containing HISDN (isosorbide dinitrate: 26 mg/kg per day; hydralazine: 50 mg/kg per day) for 4 weeks. Aldosterone infusion increased tail-cuff blood pressure (161±3 mm Hg) versus saline-infused mice (129±2 mm Hg). Aldosterone induced LV hypertrophy versus saline-infused mice (LV:body weight ratio: 4.2±0.1 versus 3.6±0.1 mg/g). HISDN attenuated the aldosterone-induced increased in systolic blood pressure (137±5 mm Hg) and also lowered blood pressure in saline-infused mice (114±2 mm Hg). However, HISDN did not cause LV hypertrophy regression in aldosterone-infused mice. Aldosterone increased LV end-diastolic dimensions that were not attenuated by HISDN. Similarly, neither aldosterone infusion nor HISDN affected LV end-systolic dimensions. LV ejection fraction and wet:dry lung ratio were not different between aldosterone-untreated and aldosterone-HISDN mice. However, mitral Doppler E/A ratio (a measure of diastolic function), exercise capacity, and plasma soluble vascular cell adhesion molecule 1 levels were improved in aldosterone-HISDN hearts. In conclusion, fixed-dose HISDN improved hypertension, diastolic function, and exercise capacity and reduced soluble vascular cell adhesion molecule 1 levels. There were no reductions in LV hypertrophy, cardiac fibrosis, or pulmonary congestion. These functional improvements are likely related to extracardiac effects, such as effects on the vasculature.


Key words: diastolic heart failure • hydralazine • nitrates • hypertension • exercise capacity